0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > All Other Proteins > CLEC12A > CLA-H82E6

Biotinylated Human CLEC12A / MICL / CLL-1 Protein, His,Avitag™

This product is still under development. Please contact us if you have interest in this product. We will accelerate the development process accordingly and reserve this product for you as request.
  • Synonym
    CLEC12A,MICL,CLL-1,CLL1,DCAL2,DCAL-2,CD371
  • Source
    Biotinylated Human CLEC12A, His,Avitag™ (CLA-H82E6) is expressed from human 293 cells (HEK293). It contains AA His 65 - Ala 265 (Accession # Q5QGZ9-2).
    Predicted N-terminus: Gly
  • Molecular Characterization
    Online-Res(His 65 - Ala 265) Q5QGZ9-2

    This protein carries an Avi tag at the N-terminus, followed by a polyhistidine tag.

    The protein has a calculated MW of 27.3 kDa.

  • Biotinylation
    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
  • Endotoxin
  • Formulation

    Please contact us for detailed information.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • Background
    CLEC12A (C-type lectin domain family 12 member A) is also known as CLL1, DCAL2, MICL. Clec12a is an inhibitory receptor for uric acid crystals that regulates inflammation in response to cell death. Cell surface receptor that modulates signaling cascades and mediates tyrosine phosphorylation of target MAP kinases. Evidence of distinct disease propagating stem cells in myelodysplastic syndrome (MDS) has emerged in recent years. The role of CLEC12A in MDS, however, remains to be elucidated. Furthermore, CLEC12A has been proposed as a promising marker of leukaemic stem cells in AML.
  • References
    • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

    Comments (0)

    Order Details

    Price(USD) : $350.00

    Price(USD) : $1380.00

    Promotion & Exhibitions



    Datasheet & Documentation

    Request for DMF
    DMF (Drug Master File)

    Contact Us

    +1  800-810-0816 (US)
    +86 400-682-2521 (AP)

    Questions & Comments

    This web search service is supported by Google Inc.

    totop